KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $11.1 million.

  • Supernus Pharmaceuticals' Other Working Capital Changes rose 53571.02% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year increase of 221490.51%. This contributed to the annual value of $19.4 million for FY2024, which is 569401.2% up from last year.
  • Supernus Pharmaceuticals' Other Working Capital Changes amounted to $11.1 million in Q3 2025, which was up 53571.02% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Other Working Capital Changes peaked at $28.2 million during Q2 2023, and registered a low of -$20.4 million during Q3 2023.
  • For the 5-year period, Supernus Pharmaceuticals' Other Working Capital Changes averaged around $562812.5, with its median value being -$766500.0 (2022).
  • Examining YoY changes over the last 5 years, Supernus Pharmaceuticals' Other Working Capital Changes showed a top increase of 360347.83% in 2023 and a maximum decrease of 155633.12% in 2023.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Other Working Capital Changes stood at -$4.7 million in 2021, then plummeted by 97.87% to -$9.2 million in 2022, then rose by 15.22% to -$7.8 million in 2023, then surged by 238.52% to $10.8 million in 2024, then increased by 3.09% to $11.1 million in 2025.
  • Its last three reported values are $11.1 million in Q3 2025, $2.5 million for Q2 2025, and -$7.4 million during Q1 2025.